// App-Quantinova.ai

BSH2020‐EP‐004 : Identification of a new target patient population for ibrutinib treatment

Researchers

Presenter

  • S. Jordaens

Principal Investigators

  • L. Cooksey

  • S. Bonney

  • L. Orchard

  • V. van Tendeloo

  • K. Mills

  • K. Orchard

  • B. Guinn

Medical Centers

  • Department of Biomedical Sciences, University of Hull, Hull, UK

  • Vaccine & Infectious Disease Institute, University of Antwerp,

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom

  • Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM

Locations

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Mantle cell lymphoma

  • Lymphomas

Biomarkers

  • Bone marrow tyrosine kinase gene in chromosome X protein

  • Breakpoint Cluster Region

Drug/Treatment

  • Ibrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved